INTRODUCTION
============

Anemia is a common complication among patients with chronic kidney disease (CKD), and its prevalence rises as estimated glomerular filtration rate (eGFR) decreases \[[@sfz091-B1]\]. Anemia in CKD is associated with decreased quality of life and increased risk of cardiovascular disease and mortality \[[@sfz091-B4]\]. Several mechanisms of CKD-related anemia have been implicated \[[@sfz091-B5]\], including relative erythropoietin deficiency \[[@sfz091-B7]\], decreased red cell life span \[[@sfz091-B8]\], abnormal iron metabolism \[[@sfz091-B9]\], chronic inflammation \[[@sfz091-B10]\], metabolic abnormalities \[[@sfz091-B11]\] and effects of medications such as renin angiotensin system (RAS) inhibitors \[[@sfz091-B17]\].

Several practice guidelines provide frameworks to assist clinicians with diagnosis and management of anemia in CKD patients \[[@sfz091-B2], [@sfz091-B22]\]. Among Chronic Kidney Disease Outcomes and Practice Patterns Study (CKDopps) countries, the Kidney Disease: Improving Global Outcomes (KDIGO) anemia guidelines \[[@sfz091-B22]\] are widely utilized in Brazil and the USA, while the European Renal Best Practice (ERBP) group published a position statement adapting KDIGO anemia recommendations for the European population \[[@sfz091-B25]\]. Many of the KDIGO recommendations were not graded or had low quality of evidence \[[@sfz091-B22]\]. KDIGO and ERBP recommendations differ in hemoglobin thresholds for defining anemia and in iron parameter thresholds for initiating iron therapy \[[@sfz091-B25]\]. In addition to practice variation between countries, we hypothesized there would also be substantial variation at the clinic level based on local practice patterns, individualization of treatment and nephrologist preferences.

Using data from the CKDopps, we evaluated the monitoring frequency, prevalence and management of anemia and iron deficiency in patients with CKD Stages 3--5ND in Brazil, France, Germany and the USA.

MATERIALS AND METHODS
=====================

CKDopps is an ongoing international prospective cohort study of nondialysis patients with eGFR \<60 mL/min/1.73 m^2^; study methods have been previously published \[[@sfz091-B29], [@sfz091-B30]\]. Participants were sequentially or randomly selected from national samples of nephrologist-run CKD clinics in Brazil, France, Germany and the USA. Ethics approval for CKDopps was obtained from a central institutional review board (study number: 14004-05).

This investigation utilized data available from 1 January 2013 until 13 April 2018, which included patients entering CKDopps at different time points over this 5.3-year period. Patients were excluded if (i) baseline demographics/medical history questionnaire were not completed, (ii) no laboratory data were reported or (iii) no hemoglobin measurements were reported either during the 6 months prior to enrollment or within 6 months of a reported eGFR during follow-up (see [Supplementary data](#sup1){ref-type="supplementary-material"}, [Figure S1](#sup1){ref-type="supplementary-material"} for study flow diagram).

The hemoglobin measurement used for the cross-sectional analyses (index hemoglobin) was usually the most recent measurement reported during the 6 months prior to the study enrollment date. In patients who did not have hemoglobin reported prior to enrollment, the first available measurement during study follow-up was used, as long as the hemoglobin measurement date was within 6 months of a reported eGFR. For analyses by CKD stage, patients contributed once to the analyses for each CKD stage, utilizing the first hemoglobin measured within 6 months at or after transition to the new CKD stage.

Anemia monitoring by CKD stage was assessed by time from index hemoglobin measurement to the next hemoglobin measurement within a particular CKD stage and presented as cumulative incidence functions. Follow-up time was censored at the earliest of when a patient switched to a different CKD stage, date of last available lab data or end of patient's follow-up.

Iron status was assessed by the percentage of patients with (i) both ferritin \<100 ng/mL and iron saturation (TSAT) \<20%; (ii) one of: ferritin \<100 ng/mL or TSAT \<20% (when both ferritin and TSAT values were available); or (iii) ferritin \<100 ng/mL or TSAT \<20% (when data for only ferritin or only TSAT were available). The closest TSAT or ferritin measurements within ±3 months of the index hemoglobin were considered concurrent measurements.

Anemia treatment with erythropoiesis stimulating agents (ESAs) and/or iron was based upon relevant prescriptions at or within 3 months after the index hemoglobin measurement; only 3% of patients with hemoglobin measurements were missing data regarding iron or ESA prescription status.

We performed a sensitivity analysis excluding patients with CKD Stage 3a, a subgroup with lower likelihood of metabolic complications of CKD. A subgroup analysis of anemia treatment after two consecutive hemoglobin measurements was also performed (data were available for Brazil, Germany and the USA for this analysis).

Standard descriptive statistics were applied for this investigation. All statistical analyses were conducted using SAS, version 9.4 (SAS Institute Inc., Cary, NC, USA).

RESULTS
=======

Patient characteristics
-----------------------

The study sample was comprised of 6766 CKD Stages 3--5ND patients from 135 CKD clinics across the four countries ([Table 1](#sfz091-T1){ref-type="table"}; [Supplementary data](#sup1){ref-type="supplementary-material"}, [Table S1](#sup1){ref-type="supplementary-material"}). By study design \[[@sfz091-B29]\], most patients had CKD Stage 4: 49% (Brazil), 42% (France), 73% (Germany) and 55% (USA). The most common reported primary causes of CKD were diabetes and hypertension in all countries, although the prevalence of diabetic kidney disease was lower in France (22%) compared with other countries (30--37%). Patients with lower hemoglobin levels displayed a higher prevalence of female sex, black race, more advanced CKD, congestive heart failure, other cardiovascular disease, diabetes and peripheral vascular disease.

###### 

Patient characteristics, by hemoglobin level and country

                                                         Brazil        France        Germany         USA                                                                                                                                                                
  --------------------------------------------------- ------------- ------------- ------------- ------------- ------------- ------------- ------------- ------------- ------------- ------------- ------------- ------------- ------------- ------------- ------------- -------------
  *N* (% in country)                                     91 (13)      255 (36)      363 (51)         709         82 (3)       744 (25)      2118 (72)       2944         127 (7)      553 (32)      1040 (60)       1720        208 (15)      521 (37)      664 (48)        1393
  Demographics                                                                                                                                                                                                                                                          
   Age (years)                                         64.0 (16.8)   65.9 (14.1)   65.7 (14.2)   65.5 (14.5)   64.0 (15.9)   67.6 (13.8)   66.8 (12.4)   67.0 (12.9)   74.1 (11.0)   74.5 (11.3)   71.3 (12.7)   72.5 (12.3)   67.2 (14.9)   70.1 (12.9)   68.2 (11.9)   68.8 (12.8)
   Female sex (%)                                          54            60            36            47            45            51            29            35            42            54            36            42            57            55            39            48
   Black race (%)                                          39            33            26            30             6             3             2             3            --            --            --            --            36            24            15            22
   Body mass index (kg/m^2^)                           27.8 (5.7)    27.6 (4.8)    28.2 (5.7)    27.9 (5.4)    27.7 (6.6)    28.8 (6.7)    28.7 (5.5)    28.7 (5.9)    27.8 (5.8)    29.0 (5.7)    29.6 (5.4)    29.2 (5.5)    31.3 (7.8)    30.7 (7.6)    31.5 (6.5)    31.2 (7.1)
   CKD stage (%)                                                                                                                                                                                                                                                        
    3                                                       4            23            43            31            38            35            61            54            12            17            33            26            16            22            42            31
    4                                                      51            50            48            49            44            57            36            42            86            81            67            73            50            62            50            55
    5                                                      45            27             9            20            18             8             3             4             2             2             0             1            34            16             8            15
   Reported cause of CKD (%)                                                                                                                                                                                                                                            
    Diabetes                                               39            40            32            36            26            27            19            22            33            32            28            30            44            42            31            37
    Glomerular disease                                      6            10            11            10            30            18            18            19            12             9            10            10             7             9             7             8
    Hypertension[^a^](#tblfn2){ref-type="table-fn"}        30            28            33            31            21            29            31            30            29            36            35            35            26            33            38            34
    Other                                                  25            22            24            23            24            26            32            30            26            23            28            26            23            16            24            21
  Comorbidities (%)                                                                                                                                                                                                                                                     
   Coronary artery disease                                 25            22            24            23            31            27            24            25            35            26            28            28            33            33            27            30
   Cerebrovascular disease                                 14             9            12            11            12            12            12            12            --            --            --            --            10            12            12            12
   Congestive heart failure                                23            15            15            16            21            14            13            13            16            12            10            11            26            17            13            16
   Myocardial infarction                                    7             6             9             8            16            14            13            13             8             6            10             9            11             9             7             9
   Hypertension[^b^](#tblfn3){ref-type="table-fn"}         91            91            92            92            92            91            91            91            81            84            87            86            93            93            92            93
   Peripheral vascular disease                             26            23            23            23            24            21            19            20            --            --            --            --            24            17            12            16
   Other cardiovascular disease                            18            12            15            14            29            29            27            28            21            14            13            14            20            19            20            20
   Cancer (nonskin)                                         8             8            10             9            23            20            22            21            --            --            --            --            20            14            18            17
   Diabetes                                                55            52            46            47            46            48            41            43            47            45            43            43            64            62            52            55
   Gastrointestinal bleeding                                7             2             2             3             0             1             1             1             5             2             1             1             2             2             1             1
   HIV/AIDS                                                 2             2             0             1             2             2             1             1             0             0             0             0             0             1             2             1
   Lung disease                                             8             5            10             8            19            12             9            10             6             6             7             7            18            13             9            12
   Neurologic disease                                      18            11            12            12             1             3             2             2             2             2             2             2             5             5             3             4
   Psychiatric disorder                                    17            14            11            13             6            10             9             9            --            --            --            --            21            15            14            15
   Recurrent cellulitis/gangrene                           11             5             6             6             0             2             1             2            --            --            --            --             9             5             3             5

Values are represented as mean (SD) or prevalence.

Includes vascular nephropathy in France.

Includes patients who received anti-hypertensive treatment in France.

Monitoring of hemoglobin and iron indices
-----------------------------------------

[Figure 1](#sfz091-F1){ref-type="fig"} shows the cumulative incidence of a subsequent hemoglobin measurement over 1 year, by CKD stage and index hemoglobin level. Hemoglobin was measured more frequently with advancing CKD, with 60% of patients having their next hemoglobin measurement in 6, 4 and 3 months, respectively, for CKD Stages 3, 4 and 5ND patients. Similarly, hemoglobin was measured more frequently among patients with lower index hemoglobin levels, with 60% having their next hemoglobin level measured in 5, 4 and 3 months, respectively, for patients with index hemoglobin levels of ≥12, 10 to \<12 and \<10 g/dL. Cumulative incidence of hemoglobin measurements differed little across countries. By comparison, almost all patients had repeat serum creatinine measurements after study entry, with median times until the next creatinine measurement of approximately 4 and 2 months, respectively, for CKD Stages 3a and 5ND patients.

![Cumulative incidence of hemoglobin measurement. (**a**) By CKD stage. (**b**) By hemoglobin level. Graph by CKD stage allows patients to contribute once for each stage. French data are excluded from the graph as the laboratory measurements are collected according to a predefined study protocol. Time 0 is the first hemoglobin (Hgb) measurement. KDIGO 2012 anemia guidelines \[[@sfz091-B21]\]: (i) for nondialysis CKD patients with anemia not being treated with an ESA, hemoglobin should be measured when clinically indicated and at least every 3 months in patients with CKD Stages 3--5ND; (ii) for nondialysis CKD patients being treated with an ESA, hemoglobin should be measured at least monthly during the initiation phase of ESA therapy, whereas hemoglobin should be measured at least every 3 months during the maintenance phase of ESA therapy.](sfz091f1){#sfz091-F1}

[Figure 2](#sfz091-F2){ref-type="fig"} shows measurement of TSAT and serum ferritin within ±3 months of the index hemoglobin measurement. Iron indices were measured more commonly in patients having lower hemoglobin levels and more advanced CKD. Measurement rates were highest in Germany, with approximately 50% of CKD Stages 3b and 4 patients and 75% of CKD Stage 5ND patients having a measured TSAT or ferritin. In Brazil and the USA, TSAT or ferritin was measured for 23--50% of patients by CKD stage. Among patients with hemoglobin \<10 g/dL, measurement of TSAT or ferritin was least common in the USA (53%), versus 75% in Germany and 61% in Brazil. Ferritin and TSAT were usually measured together. Similar results were seen in a sensitivity analysis of iron status measurement excluding CKD Stage 3a patients.

![Measurement of iron parameters, by country. (**a**) By CKD stage. (**b**) By hemoglobin level. Patients could contribute once for each CKD stage experienced during the study for (a). Measurement within ±3 months from hemoglobin (Hgb) value. French data are excluded from the graph as the laboratory measurements are collected according to a predefined study protocol.](sfz091f2){#sfz091-F2}

Prevalence of anemia and iron deficiency
----------------------------------------

Within all CKD stages, mean hemoglobin was highest in France, intermediate in Brazil and Germany, and lowest in the USA ([Table 1;](#sfz091-T1){ref-type="table"}[Figure 3](#sfz091-F3){ref-type="fig"}). In all countries, the prevalence of anemia was higher among patients with lower eGFR and in females than males, though this difference was less pronounced at higher CKD stages ([Figure 3](#sfz091-F3){ref-type="fig"}; [Supplementary data](#sup1){ref-type="supplementary-material"}, [Figure S2](#sup1){ref-type="supplementary-material"}). The prevalence of low hemoglobin levels was substantial in advanced CKD, particularly for females: 37% of the USA and 17--26% of French, German and Brazilian CKD Stage 5ND females had index hemoglobin levels \<10 g/dL ([Supplementary data](#sup1){ref-type="supplementary-material"}, [Figure S2](#sup1){ref-type="supplementary-material"}).

![Hemoglobin distribution, by country and CKD stage. Patients could contribute once for each CKD stage experienced during the study for (a). First hemoglobin (Hgb) for each stage was taken if there were multiple measures.](sfz091f3){#sfz091-F3}

Median serum ferritin levels were higher with advancing CKD and with lower hemoglobin levels across all four countries ([Figure 4](#sfz091-F4){ref-type="fig"}). By contrast, TSAT did not vary with CKD stage in a consistent pattern across the four CKDopps countries ([Figure 5](#sfz091-F5){ref-type="fig"}). However, low TSAT levels (\<20%) were 1.5- to 2-fold more common at low (\<10 g/dL) versus higher (≥12 g/dL) hemoglobin levels, with 48--62% of patients having TSAT \<20% among patients with hemoglobin \<10 g/dL in France, Germany and the USA. TSAT levels by hemoglobin level were generally higher in Brazil compared with all other countries.

![Serum ferritin distribution, by country. (**a**) By CKD stage. (**b**) By hemoglobin level. Patients could contribute once for each CKD stage experienced during the study for (a). Ferritin values within ±3 months from hemoglobin (Hgb) value.](sfz091f4){#sfz091-F4}

![TSAT distribution, by country. (**a**) By CKD stage. (**b**) By hemoglobin level. Patients could contribute once for each CKD stage experienced during the study for (a). TSAT values within ±3 months from hemoglobin (Hgb) value.](sfz091f5){#sfz091-F5}

Prevalence of iron deficiency was assessed among patients with at least one available iron lab parameter ([Figure 6](#sfz091-F6){ref-type="fig"}). Across all CKD stages, 8--18% of patients had absolute iron deficiency (both TSAT \<20% and ferritin \<100 ng/mL), while 15--34% of patients had incongruent iron parameters \[either TSAT \<20% and ferritin \>100 ng/mL (functional iron deficiency) or TSAT \>20% and ferritin \<100 ng/mL\]. Approximately 3--17% of patients across CKD stages had either TSAT \<20% (with no ferritin available) or ferritin \<100 ng/mL (with no TSAT available).

![Iron (Fe) status, by country. (**a**) By CKD stage. (**b**) By hemoglobin level. Patients could contribute once for each CKD stage experienced during the study for (a). Ferritin and TSAT values within ±3 months from hemoglobin value in (b).](sfz091f6){#sfz091-F6}

Prescription of iron and ESAs
-----------------------------

Prescription of iron supplementation and ESAs was more common among patients with lower eGFR ([Figure 7a](#sfz091-F7){ref-type="fig"}) and lower hemoglobin levels ([Figure 7b](#sfz091-F7){ref-type="fig"}). Among patients with hemoglobin \<10 g/dL, 48% in the USA, 58% in Brazil, 66% in France and 70% in Germany were prescribed an ESA or iron in the 3 months following hemoglobin measurement. Among patients prescribed anemia treatment: (i) for patients having hemoglobin \<10 g/dL, an ESA, either alone or in combination with iron, was the most common therapy; and (ii) for patients with hemoglobin 10--12 g/dL, approximately 68% in the USA and 45--50% in all other countries were prescribed supplemental iron alone without an ESA. The most commonly prescribed ESA was epoetin alfa in Brazil and Germany, and darbepoetin alfa in France and the USA. Among patients with ferritin \<100 ng/mL or TSAT \<20%, 27--44% of patients who also had hemoglobin \<12 g/dL were prescribed iron supplementation, compared with 40--50% of patients with hemoglobin \<10 g/dL. In all countries, prescription of iron was higher for patients having TSAT \<20% or ferritin \<100 ng/mL, versus having TSAT ≥20% and ferritin ≥100 ng/mL ([Supplementary data](#sup1){ref-type="supplementary-material"}, [Table S2](#sup1){ref-type="supplementary-material"}). The opposite was seen regarding ESA prescription, with ESA prescription typically being higher among patients with TSAT ≥20% and ferritin ≥100 ng/mL versus having TSAT \< 20% or ferritin \<100 ng/mL. Among patients prescribed iron, intravenous (IV) iron prescription was greater among patients with lower hemoglobin concentrations, ranging across hemoglobin categories from 5% to 18% IV iron prescription in the USA, 6% to 21% in France, 8% to 41% in Brazil and 30% to 54% in Germany ([Supplementary data](#sup1){ref-type="supplementary-material"}, [Table S3](#sup1){ref-type="supplementary-material"}). Similar results for TSAT and ferritin distributions and ESA/iron prescriptions were obtained in sensitivity analyses excluding CKD Stage 3a patients.

![Prescription of ESAs and iron (oral or IV), by country. (**a)** By CKD stage. (**b**) By hemoglobin level. Patients could contribute once for each CKD stage experienced during the study for (a). Prescription within 3 months subsequent to hemoglobin measurement. Graph by CKD stage allows patients to contribute once for each stage. ESA = Erythropoiesis-stimulating agent.](sfz091f7){#sfz091-F7}

Overall, ESA use was more common in Brazil (16%) and Germany (16%) than in France (9%) and the USA (8%). Among patients with hemoglobin \<10 g/dL, the percentage of patients receiving ESA was 28% in the USA, 39% in Brazil, 52% in France and 57% in Germany ([Supplementary data](#sup1){ref-type="supplementary-material"}, [Table S3](#sup1){ref-type="supplementary-material"}).

A subgroup analysis demonstrated that 86% of patients with index hemoglobin \<10 mg/dL but not treated with iron or ESA within 3 months after the index hemoglobin had a subsequent hemoglobin measurement during follow-up, of which 62% had hemoglobin \<10 mg/dL on repeat measurement. Twelve percent of patients with persistent hemoglobin \<10 mg/dl on two consecutive measurements were treated with either iron or ESA within 3 months after the second hemoglobin \<10 mg/dL (9% in Brazil, 13% in Germany and 12% in the USA) ([Supplementary data](#sup1){ref-type="supplementary-material"}, [Table S4](#sup1){ref-type="supplementary-material"}).

Between-clinic variation in anemia measures and treatment
---------------------------------------------------------

Large variability was seen across CKD clinics in each country in measurement of anemia parameters, prevalence of anemia, iron status, and prescription of iron and ESAs, among patients with CKD Stages 3b--4 ([Supplementary data](#sup1){ref-type="supplementary-material"}, [Figure S3](#sup1){ref-type="supplementary-material"}). Germany had the highest use of ESA and iron treatments, and highest prevalence of ferritin and TSAT measurement, as well as the greatest inter-clinic variability in monitoring and anemia treatment practices. Higher inter-clinic variability in anemia prevalence and iron status was observed in Brazil compared with other countries.

DISCUSSION
==========

Our study demonstrates variations in the evaluation and prevalence of anemia and iron deficiency, and related treatment of CKD patients. Hemoglobin levels were lowest in the USA and highest in France. A high proportion of patients received no recorded treatment for anemia.

The frequency of hemoglobin measurement was similar among Brazil, Germany and the USA. However, measurement of iron parameters was much higher in Germany than in Brazil and the USA. The KDIGO guidelines provide clear recommendations for frequency of hemoglobin measurement based on anemia status and ESA therapy, while specific recommendations for iron status monitoring are provided only in the context of ESA therapy, and clinical discretion is recommended in other circumstances \[[@sfz091-B22]\]. Nevertheless, the high proportion of patients without iron indices measured in this analysis highlights an area for improvement in care.

Our findings indicate a high prevalence of iron deficiency, as well as iron deficiency anemia (IDA), corroborating publications using different methods and study samples \[[@sfz091-B6], [@sfz091-B31]\]. Among these, a study assessing bone marrow iron stores found nearly half of CKD 3--5ND patients with hemoglobin \<11 g/dL were iron-depleted \[[@sfz091-B32]\]. Data from the general population sample in National Health and Nutrition Examination Survey (NHANES) indicated that approximately 60% of men and 70% of women with creatinine clearance \<60 mL/min had ferritin \<100 ng/mL or TSAT \<20% \[[@sfz091-B33]\].

Median ferritin levels varied inversely with hemoglobin levels, and were higher in CKD Stage 5ND despite higher anemia prevalence with CKD progression. In contrast, no consistent pattern of TSAT distribution by CKD stage was discernable across countries, whereas TSAT \<20% was more common at lower hemoglobin levels. Ferritin and TSAT demonstrated opposite associations with hemoglobin levels, thereby reinforcing the central role of inflammation in the pathogenesis of anemia of CKD. These findings are supportive of previous studies suggesting that TSAT \<20% is more sensitive than ferritin \<100 ng/mL for iron deficiency in advanced CKD \[[@sfz091-B33], [@sfz091-B34]\]. While low ferritin (\<100 ng/mL) is specific for iron deficiency, elevated ferritin levels may be seen in iron-deficient patients due to inflammation, malnutrition, infection or malignancy.

We observed that a high proportion of patients with anemia and either ferritin \<100 ng/mL or TSAT \<20% were not treated with iron, even among those with persistent hemoglobin \<10 g/dL on two consecutive measurements. There is likely high variability in nephrologists' thresholds for treatment in nondialysis CKD patients, perhaps because guidelines reflect uncertainty about optimal care. For example, the KDIGO anemia guidelines contain a Grade 2C suggestion (low-quality evidence) to consider iron therapy in anemic patients with TSAT \<30% and ferritin \<500 ng/mL, indicating a very wide threshold \[[@sfz091-B22]\]. Following this recommendation, data from our study indicate that approximately 75% of anemic patients merit consideration for iron therapy. Conversely, the ERBP position statement suggests iron therapy be initiated if TSAT is \<25% and ferritin is \<200 ng/mL, or if there is absolute iron deficiency (TSAT \<20% and ferritin \<100 ng/mL). Among patients with hemoglobin \<12 g/dL plus either TSAT \<20% or ferritin \<100 ng/mL, treatment with iron therapy was more prevalent in Germany, Brazil and the USA (43--44%), compared with France (27%) ([Supplementary data](#sup1){ref-type="supplementary-material"}, [Table S2](#sup1){ref-type="supplementary-material"}). While this variation may partially reflect differences in guidelines commonly utilized in each region (ERBP in European countries versus KDIGO in USA and Brazil), the differences in treatment between Germany and France suggest that additional factors are at play. For example, the lower severity of anemia observed among patients in France likely contributed to their lower rate of iron therapy prescription.

There is no current consensus on the optimal administration route for iron in nondialysis CKD patients. In this analysis, oral iron was far more commonly prescribed than IV iron. In addition to its gastrointestinal side effects, oral iron may not be effectively absorbed in the setting of high hepcidin levels, which are associated with inflammation \[[@sfz091-B35]\]. Clinical trials comparing oral with IV iron in patients with CKD and IDA demonstrated inconsistent findings regarding cardiovascular and infection outcomes \[[@sfz091-B36], [@sfz091-B37]\]. This analysis did not assess use of new iron-based phosphate binders such as ferric citrate \[[@sfz091-B38], [@sfz091-B39]\].

The international PRE‐dialysis Survey on Anemia Management \[[@sfz091-B40]\] and a recent US study of Medicare and commercially insured patients report that 13 and 7% of older CKD patients were treated with ESAs and IV iron, respectively \[[@sfz091-B41]\]. That study, in contrast to ours, relied on diagnosis codes, had no data on oral iron prescription, and did not report whether patients were followed in nephrology clinics.

The KDIGO guidelines recommend that ESAs generally not be initiated when hemoglobin is ≥10.0 g/dL, but also indicate that individualization of therapy is reasonable \[[@sfz091-B22]\]. ERBP offers a similar stance, suggesting ESA initiation at hemoglobin values between 9 and 10 g/dL, with consideration of initiation at higher hemoglobin levels in patients with worsening ischemic symptoms associated with anemia \[[@sfz091-B25]\]. Preliminary data from the CKDopps nephrologist practice survey indicate that the most common hemoglobin threshold for prescribing ESA is ≤9 g/dL in the USA, ≤9.5 g/dL in France and ≤10 g/dL in Brazil \[[@sfz091-B42]\]. The lower hemoglobin threshold for ESA initiation favored among US nephrologists may explain the relatively lower ESA prescription rate in the USA compared with other CKDopps countries. Differences in guideline use, reimbursement programs, medication availability and use of protocols for anemia management not captured in this analysis presumably also explain some of the between-country variation in iron and ESA prescription, as well as the dramatic clinic-level variation we report within countries. Also of note, hemoglobin levels were generally highest in France, within each CKD stage and among both males and females, despite a comparable proportion treated for anemia (by hemoglobin category) as in Brazil and the USA, and a lower proportion than in Germany. Explanations for this observation beyond differences in guidelines and anemia management practices merit investigation, and likely include differences in patient characteristics between countries, such as CKD etiology (lower prevalence of diabetic kidney disease in France), and the percentage of black patients who displayed lower hemoglobin levels than other patients---consistent with the findings of Matos *et al*. \[[@sfz091-B43]\] in Brazil. Variations in use of medications affecting hemoglobin levels such as RAS inhibitors may also contribute to differences in mean hemoglobin levels between countries.

Major clinical trials of ESA use in CKD have demonstrated either no benefit or greater harm with normalizing hemoglobin, compared with lower targets, in outcomes including mortality, cardiovascular events and time to dialysis \[[@sfz091-B44]\]. As a result, most guidelines recommend a hemoglobin target range of 10--12 g/dL \[[@sfz091-B47]\]. However, our results demonstrate undertreatment to this target range. Further, published data indicate that hemoglobin levels are lower at dialysis initiation than in our sample of patients with early CKD Stage 5ND. It is probable that earlier treatment would limit the rapid worsening of anemia seen in the period prior to dialysis start, and plausible that this may be one part of a multifaceted strategy to lower the excessively high mortality that characterizes the early dialysis period \[[@sfz091-B48], [@sfz091-B49]\].

With respect to patient-reported outcomes (PROs), improved quality of life and fatigue scores were observed in the higher hemoglobin target group in the Cardiovascular Risk Reduction by Early Anemia Treatment with Epoetin Beta Trial (CREATE) \[[@sfz091-B44]\] and Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) trials \[[@sfz091-B45]\], respectively, but not in the Correction of Hemogloblin and Outcomes in Renal Insufficiency (CHOIR) trial \[[@sfz091-B46]\]. To date, there has been insufficient research on the impact of CKD-related anemia and its treatment on PROs, such as functional status, activities of daily living or ability to work. The question of whether anemia treatment in advanced CKD can help to maintain patients' lifestyles or even delay the start of kidney replacement therapy by potentially limiting symptoms remains of high importance to patients and health-care providers.

While the cross-sectional design of this study limits causal inference, the design was appropriate to address the study's goal to describe anemia management practices among CKD patients. Another limitation is that this analysis is restricted to nephrology practices participating in CKDopps in four countries, and therefore is not generalizable to other settings. We were unable to differentiate missing data from true clinical variation in laboratory monitoring practices. However, laboratory data collection was fairly complete, as other laboratory data such as creatinine were collected more frequently than anemia parameters. We could not assess routine laboratory monitoring practices in France, where the study has a mandated laboratory collection protocol. The analysis of iron deficiency was limited by the large number of patients with no iron measurements in Brazil, Germany and the USA. There may have been underreporting of IV iron and ESA therapy due to their intermittent administration, and this analysis did not assess rates of blood transfusions.

In summary, this international analysis of anemia management in patients with nondialysis CKD treated in nephrology clinics identified substantial clinic- and country-level variation in prevalence of anemia and iron deficiency, frequency of anemia monitoring and treatment. We identified a high proportion of patients without measurement of iron parameters, and also patients with IDA who are not treated with iron or ESA, especially in the USA and Brazil. Anemia monitoring and treatment are a ripe area for quality improvement in CKD care. Further research is needed to gain understanding of determinants of anemia in CKD, as well as the effect of its treatment on PROs and clinical outcomes.

Supplementary Material
======================

###### 

Click here for additional data file.
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